BusinessRelypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa® (patiromer) With or Without FoodBy Nasdaq OMXMay 8, 2018, 12:01 PM UTC
BusinessRelypsa Funds Three Innovative Research Projects on Hyperkalemia and Associated DisordersBy Nasdaq OMXApr 16, 2018, 8:00 PM UTC
BusinessRelypsa Presents Patiromer Clinical Trial Data on Serum Potassium in Patients with Hyperkalemia at the National Kidney Foundation 2018 Spring Clinical MeetingsBy Nasdaq OMXApr 11, 2018, 12:01 PM UTC
